Sentiment · ELV
Lobbying Spend for ELV
AI-generated plain-English read of lobbying spend for ELV. Updated daily.
Heavy lobbying, trending higher
highHeavy and rising. The company is building a more serious DC presence quarter over quarter — watch for a policy catalyst that would explain the ramp.
What will probably happen
- A rising trend without an obvious single catalyst suggests broadening DC engagement — a structural shift, not a one-quarter reaction.
- Spend is spread across many issue areas — the company has diverse regulatory exposure and is fighting on multiple fronts simultaneously.
What to do
- If you HOLD this stock
- Deepening DC engagement — hold your position but monitor the primary issue area for policy news that could catalyze a move in either direction.
- If you're EVALUATING this stock
- Heavy DC presence is a recurring cost and risk factor — factor in the regulatory environment when sizing. Requires research into the primary issue areas.
- If you trade OPTIONS
- No clean options signal derived from this lobbying read.
13 quarters of history with $31.43M in total spend — sufficient data for a reliable trajectory read.
Technical details
Technical analysis
- Spend tier
- Heavy
- Trajectory
- Rising
- Last quarter
- $1.86M
- Last 4Q total
- $10.91M
- Prior 4Q total
- $9.81M
- Top issue area
- HEALTH ISSUES (56% of spend)
- Top registrant
- ELEVANCE HEALTH, INC. (83% of spend)
- Registrant base
- In house
- Quarters on record
- 13
- Unique issue areas
- 9
- Unique registrants
- 11
- Issue concentration
- Broad
Key levels
| Level | Value |
|---|---|
| total amount | 31,430,000 |
| last 4q total | 10,915,000 |
| top issue pct | 0.563 |
| prior 4q total | 9,810,000 |
| top registrant pct | 0.831 |
| last quarter amount | 1,865,000 |
Caveats
- Lobbying disclosures are quarterly and reflect activity already past. The signal is structural, not timing.
- The primary registrant appears to be an in-house government-affairs operation. In-house lobbying may not be captured in full by third-party disclosure data.